BNKL OTC
Bionik Laboratories Corp.
1W: +0.0%
1M: +0.0%
3M: +0.0%
YTD: +0.0%
1Y: +0.0%
3Y: -100.0%
5Y: -100.0%
$0.00
+0.00 (+0.00%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$2M
+41.7% ▲
5Y CAGR: +12.8%
Gross Profit
$990K
+3.8% ▲
5Y CAGR: +11.1%
Operating Income
-$5M
-1.1% ▼
Net Income
-$5M
+52.5% ▲
EPS (Diluted)
$-0.72
+59.6% ▲
EBITDA
-$5M
+49.6% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
| Revenue | $3M | $2M | $1M | $1M | $2M |
| YoY Growth | +228.7% | -33.7% | -44.6% | +6.7% | +41.7% |
| Cost of Revenue | $2M | $893K | $270K | $320K | $815K |
| Gross Profit | $2M | $1M | $924K | $953K | $990K |
| Gross Margin | 49.8% | 58.5% | 77.4% | 74.8% | 54.8% |
| R&D Expenses | $3M | $4M | $1M | $999K | $903K |
| SG&A Expenses | $8M | $8M | $6M | $5M | $5M |
| Operating Expenses | $11M | $12M | $7M | $6M | $6M |
| Operating Income | -$7M | -$11M | -$6M | -$5M | -$5M |
| Operating Margin | -224.6% | -522.2% | -515.8% | -374.7% | -267.3% |
| Interest Expense | $3M | $182K | $405K | $825K | $107K |
| Income Before Tax | -$11M | -$25M | -$14M | -$10M | -$5M |
| Tax Expense | -$507 | $0 | $0 | $0 | $0 |
| Net Income | -$11M | -$25M | -$14M | -$10M | -$5M |
| Net Margin | -325.2% | -1157.9% | -1141.3% | -817.1% | -274.0% |
| EPS (Diluted) | $-4.47 | $-5.60 | $-2.66 | $-1.78 | $-0.72 |
| EBITDA | -$7M | -$24M | -$13M | -$9M | -$5M |
| Shares Outstanding | 2M | 4M | 5M | 6M | 7M |